BridgeBio Reports New Data on Acoramidis Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Should l Buy BBIO?
Source: NASDAQ.COM
- Clinical Trial Results: BridgeBio Pharma's Phase 3 ATTRibute-CM study demonstrates Acoramidis' disease-modifying effects across clinical outcomes, biomarkers, and functional capacity, reinforcing its potential in treating transthyretin amyloid cardiomyopathy.
- FDA Approval Context: Acoramidis received FDA approval in November 2024 to reduce cardiovascular death and related hospitalizations, marking a significant milestone in the treatment of transthyretin-mediated amyloidosis.
- Biomarker Association: New data indicates a positive correlation between treatment-related serum transthyretin (sTTR) levels and early markers of disease progression, with higher sTTR levels and lower variability linked to improved survival outcomes.
- Reduced Heart Failure Risk: Patients treated with Acoramidis experienced a 41% reduction in heart failure risk, a 34% decrease in cardiovascular hospitalizations compared to placebo, and a 28% reduction in all-cause mortality, highlighting its significant clinical advantages.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 65.320
Low
85.00
Averages
98.50
High
157.00
Current: 65.320
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
Cardiovascular Disease Costs Surge, AI Technology Becomes Key
- Cost Warning for Cardiovascular Disease: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment approaches for cardiac patients, potentially leading to significant industry transformation.
- Growth of AI Cardiology Market: The global AI cardiology market is valued at $2.78 billion this year and is projected to exceed $14 billion by 2034, driving health systems to accelerate the deployment of machine learning tools to address diagnostic backlogs, thereby enhancing medical efficiency and patient satisfaction.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform, VMS+™ 4.0, at the AEPC annual meeting in Italy, which can convert standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI while significantly reducing equipment costs and wait times.
- International Collaborations and Market Expansion: VentriPoint has established relationships with multiple international partners, including Lishman Global, which is applying for regulatory approval in China, and collaborations in Costa Rica and Indigenous communities in Canada, demonstrating its growth potential and strategic positioning in the global cardiac diagnostics market.
See More
BridgeBio's Encaleret Shows Promising Phase 3 Results for ADH1
- Successful Clinical Trial: At the 2026 European Congress of Endocrinology, BridgeBio presented Phase 3 CALIBRATE trial results, showing that 76% of participants on encaleret achieved target serum and urine calcium levels at Week 24, a significant increase from 4% on conventional therapy, highlighting the drug's potential in treating ADH1.
- Market Opportunity: BridgeBio anticipates a U.S. launch of encaleret in early 2027, which, if approved, would be the first therapy specifically indicated for ADH1, addressing the urgent needs of nearly 2,000 diagnosed patients in the U.S. and indicating a substantial market opportunity.
- Favorable Safety Profile: No discontinuations were reported in the encaleret group, and the rate of serious adverse events was similar to the control group, indicating a good safety and tolerability profile that supports future market adoption.
- Future Research Plans: BridgeBio plans to initiate the RECLAIM-HP Phase 3 clinical study in Summer 2026, further exploring encaleret's applications in chronic hypoparathyroidism, thereby expanding its indications and enhancing the company's competitiveness in the genetic disease sector.
See More
BridgeBio Reports New Data on Acoramidis Efficacy
- Clinical Trial Results: BridgeBio Pharma's Phase 3 ATTRibute-CM study demonstrates Acoramidis' disease-modifying effects across clinical outcomes, biomarkers, and functional capacity, reinforcing its potential in treating transthyretin amyloid cardiomyopathy.
- FDA Approval Context: Acoramidis received FDA approval in November 2024 to reduce cardiovascular death and related hospitalizations, marking a significant milestone in the treatment of transthyretin-mediated amyloidosis.
- Biomarker Association: New data indicates a positive correlation between treatment-related serum transthyretin (sTTR) levels and early markers of disease progression, with higher sTTR levels and lower variability linked to improved survival outcomes.
- Reduced Heart Failure Risk: Patients treated with Acoramidis experienced a 41% reduction in heart failure risk, a 34% decrease in cardiovascular hospitalizations compared to placebo, and a 28% reduction in all-cause mortality, highlighting its significant clinical advantages.
See More
Acoramidis Shows Significant Benefits in ATTR-CM Study
- Significant Clinical Effects: Acoramidis demonstrated early and significant increases in serum transthyretin (sTTR) levels in the Phase 3 ATTRibute-CM study, reducing the risk of outpatient worsening heart failure by 41% within 30 days, showcasing its rapid impact in heart disease treatment.
- Mortality Reduction: The study revealed that Acoramidis significantly reduced sTTR variability (9.5% vs. 12.8%; p<0.001), which was associated with a decrease in all-cause mortality (HR: 0.56; p=0.014), indicating its potential in improving patient survival rates.
- Hospitalization Rate Decrease: Acoramidis achieved a statistically significant 34% reduction in cardiovascular hospitalizations compared to tafamidis (RRR: 0.66; 95% CI: 0.46–0.95), along with a favorable mortality trend, further solidifying its clinical value.
- Good Safety Profile: Acoramidis exhibited a comparable safety profile to tafamidis, with similar adverse event rates, ensuring its acceptability in clinical use and supporting its role as an effective treatment option for ATTR-CM.
See More
BridgeBio Pharma Reports Strong Q1 2026 Earnings and $500M Buyback
- Attruby Sales Growth: BridgeBio Pharma reported $180.6 million in Attruby sales for Q1 2026, reflecting a 24% increase from the previous quarter, indicating strong market performance and positioning the company for continued revenue growth.
- Significant Clinical Data: CEO Neil Kumar highlighted that Attruby demonstrated a 49% reduction in cardiovascular mortality compared to tafamidis in clinical trials, enhancing the product's competitive edge and laying a solid foundation for future sales growth.
- Share Buyback Program: The Board authorized a $500 million share repurchase program aimed at leveraging current market undervaluation to enhance shareholder value while maintaining flexibility for future investments, which is expected to positively impact the stock price.
- Financial Outlook: CFO Thomas Trimarchi indicated that operational losses are expected to stabilize over the next two quarters, with a plan to achieve breakeven by 2027, reflecting the company's confidence in financial management and strategic planning for business expansion.
See More
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
Cardiovascular Disease Costs Surge, AI Technology Becomes Key
- Cost Warning for Cardiovascular Disease: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment approaches for cardiac patients, potentially leading to significant industry transformation.
- Growth of AI Cardiology Market: The global AI cardiology market is valued at $2.78 billion this year and is projected to exceed $14 billion by 2034, driving health systems to accelerate the deployment of machine learning tools to address diagnostic backlogs, thereby enhancing medical efficiency and patient satisfaction.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform, VMS+™ 4.0, at the AEPC annual meeting in Italy, which can convert standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI while significantly reducing equipment costs and wait times.
- International Collaborations and Market Expansion: VentriPoint has established relationships with multiple international partners, including Lishman Global, which is applying for regulatory approval in China, and collaborations in Costa Rica and Indigenous communities in Canada, demonstrating its growth potential and strategic positioning in the global cardiac diagnostics market.
See More
BridgeBio's Encaleret Shows Promising Phase 3 Results for ADH1
- Successful Clinical Trial: At the 2026 European Congress of Endocrinology, BridgeBio presented Phase 3 CALIBRATE trial results, showing that 76% of participants on encaleret achieved target serum and urine calcium levels at Week 24, a significant increase from 4% on conventional therapy, highlighting the drug's potential in treating ADH1.
- Market Opportunity: BridgeBio anticipates a U.S. launch of encaleret in early 2027, which, if approved, would be the first therapy specifically indicated for ADH1, addressing the urgent needs of nearly 2,000 diagnosed patients in the U.S. and indicating a substantial market opportunity.
- Favorable Safety Profile: No discontinuations were reported in the encaleret group, and the rate of serious adverse events was similar to the control group, indicating a good safety and tolerability profile that supports future market adoption.
- Future Research Plans: BridgeBio plans to initiate the RECLAIM-HP Phase 3 clinical study in Summer 2026, further exploring encaleret's applications in chronic hypoparathyroidism, thereby expanding its indications and enhancing the company's competitiveness in the genetic disease sector.
See More
BridgeBio Reports New Data on Acoramidis Efficacy
- Clinical Trial Results: BridgeBio Pharma's Phase 3 ATTRibute-CM study demonstrates Acoramidis' disease-modifying effects across clinical outcomes, biomarkers, and functional capacity, reinforcing its potential in treating transthyretin amyloid cardiomyopathy.
- FDA Approval Context: Acoramidis received FDA approval in November 2024 to reduce cardiovascular death and related hospitalizations, marking a significant milestone in the treatment of transthyretin-mediated amyloidosis.
- Biomarker Association: New data indicates a positive correlation between treatment-related serum transthyretin (sTTR) levels and early markers of disease progression, with higher sTTR levels and lower variability linked to improved survival outcomes.
- Reduced Heart Failure Risk: Patients treated with Acoramidis experienced a 41% reduction in heart failure risk, a 34% decrease in cardiovascular hospitalizations compared to placebo, and a 28% reduction in all-cause mortality, highlighting its significant clinical advantages.
See More
Acoramidis Shows Significant Benefits in ATTR-CM Study
- Significant Clinical Effects: Acoramidis demonstrated early and significant increases in serum transthyretin (sTTR) levels in the Phase 3 ATTRibute-CM study, reducing the risk of outpatient worsening heart failure by 41% within 30 days, showcasing its rapid impact in heart disease treatment.
- Mortality Reduction: The study revealed that Acoramidis significantly reduced sTTR variability (9.5% vs. 12.8%; p<0.001), which was associated with a decrease in all-cause mortality (HR: 0.56; p=0.014), indicating its potential in improving patient survival rates.
- Hospitalization Rate Decrease: Acoramidis achieved a statistically significant 34% reduction in cardiovascular hospitalizations compared to tafamidis (RRR: 0.66; 95% CI: 0.46–0.95), along with a favorable mortality trend, further solidifying its clinical value.
- Good Safety Profile: Acoramidis exhibited a comparable safety profile to tafamidis, with similar adverse event rates, ensuring its acceptability in clinical use and supporting its role as an effective treatment option for ATTR-CM.
See More
BridgeBio Pharma Reports Strong Q1 2026 Earnings and $500M Buyback
- Attruby Sales Growth: BridgeBio Pharma reported $180.6 million in Attruby sales for Q1 2026, reflecting a 24% increase from the previous quarter, indicating strong market performance and positioning the company for continued revenue growth.
- Significant Clinical Data: CEO Neil Kumar highlighted that Attruby demonstrated a 49% reduction in cardiovascular mortality compared to tafamidis in clinical trials, enhancing the product's competitive edge and laying a solid foundation for future sales growth.
- Share Buyback Program: The Board authorized a $500 million share repurchase program aimed at leveraging current market undervaluation to enhance shareholder value while maintaining flexibility for future investments, which is expected to positively impact the stock price.
- Financial Outlook: CFO Thomas Trimarchi indicated that operational losses are expected to stabilize over the next two quarters, with a plan to achieve breakeven by 2027, reflecting the company's confidence in financial management and strategic planning for business expansion.
See More
